Trastuzumab/hyaluronidase

Trastuzumab/hyaluronidase is a medication used in the treatment of HER2-positive breast cancer. It is a combination of trastuzumab, a monoclonal antibody, and hyaluronidase, an enzyme that increases the absorption of the drug.

Etymology

The name "trastuzumab" is derived from the Latin "trans", meaning "across", and "tuzumab", a common suffix for monoclonal antibodies. The name "hyaluronidase" comes from "hyaluronic acid", the substance it breaks down, and "-ase", a suffix used in biochemistry to denote enzymes.

Pharmacology

Trastuzumab works by binding to the HER2 receptor on cancer cells, blocking them from receiving growth signals. Hyaluronidase increases the absorption of trastuzumab, allowing it to reach more cancer cells.

Clinical use

Trastuzumab/hyaluronidase is used in the treatment of HER2-positive breast cancer. It is administered by subcutaneous injection.

Side effects

Common side effects of trastuzumab/hyaluronidase include fatigue, joint pain, diarrhea, injection site reactions, upper respiratory tract infection, rash, muscle pain, nausea, and headache.

See also

• Monoclonal antibodies
• Breast cancer
• HER2/neu

Trastuzumab/hyaluronidase Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski